Jump Financial’s Prelude Therapeutics PRLD Stock Holding History

Jump Financial’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,534	Closed	-$32.2K	–	1930
2024 Q3	$32.2K	Buy	+15,534	New	+$71.9K	﹤0.01%	1563
2022 Q1	–	Sell	-36,900	Closed	-$459K	–	1833
2021 Q4	$459K	Buy	+36,900	New	+$600K	0.03%	693
2021 Q3	–	Sell	-13,700	Closed	-$392K	–	1420
2021 Q2	$392K	Buy	13,700 +7,400	+117%	+$263K	0.04%	559
2021 Q1	$273K	Buy	+6,300	New	+$418K	0.03%	642

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jump Financial's PRLD Position: Q4 2024 in Review

Jump Financial sold out of Prelude Therapeutics (PRLD) in Q4 2024, closing a stake of 15,534 shares — an estimated $32.2K sold.

Jump Financial first reported a position in PRLD in Q1 2021 and held it in 4 quarters. The position peaked at $459K in Q4 2021. 62 funds tracked by Wall St. Rank hold PRLD as of Q4 2024.

Jump Financial reported no remaining Prelude Therapeutics position as of Q4 2024 after selling out during the quarter.
Jump Financial sold 15,534 Prelude Therapeutics shares in Q4 2024, an estimated $32.2K.
Jump Financial first reported a position in Prelude Therapeutics in Q1 2021 and held it in 4 quarters.
Jump Financial's Prelude Therapeutics position peaked at $459K in Q4 2021.
62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2024.

Based on Jump Financial's 13F filing for Q4 2024, filed 13 Feb 2025.